Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Desmopressin testing in von Willebrand disease: Lowering the burden.
Heijdra JM, Atiq F, Al Arashi W, Kieboom Q, Wuijster E, Meijer K, Kruip MJHA, Leebeek FWG, Cnossen MH; OPTI‐CLOT Study Group. Heijdra JM, et al. Res Pract Thromb Haemost. 2022 Sep 26;6(6):e12784. doi: 10.1002/rth2.12784. eCollection 2022 Aug. Res Pract Thromb Haemost. 2022. PMID: 36186107 Free PMC article.
One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients.
de Jager NCB, Bukkems LH, Heijdra JM, Hazendonk CHCAM, Fijnvandraat K, Meijer K, Eikenboom J, Laros-van Gorkom BAP, Leebeek FWG, Cnossen MH, Mathôt RAA; OPTI-CLOT group. de Jager NCB, et al. Among authors: heijdra jm. J Thromb Haemost. 2020 Feb;18(2):295-305. doi: 10.1111/jth.14652. Epub 2019 Oct 21. J Thromb Haemost. 2020. PMID: 31557387 Free PMC article.
Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study.
Heijdra JM, Al Arashi W, de Jager NCB, Cloesmeijer ME, Bukkems LH, Zwaan CM, Leebeek FWG, Mathôt RAA, Cnossen MH; OPTI-CLOT Study Group. Heijdra JM, et al. BMJ Open. 2022 Feb 15;12(2):e049493. doi: 10.1136/bmjopen-2021-049493. BMJ Open. 2022. PMID: 35168962 Free PMC article.
von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.
van Moort I, Bukkems LH, Heijdra JM, Schutgens REG, Laros-van Gorkom BAP, Nieuwenhuizen L, van der Meer FJM, Fijnvandraat K, Ypma P, de Maat MPM, Leebeek FWG, Meijer K, Eikenboom J, Mathôt RAA, Cnossen MH; OPTI-CLOT Study Group. van Moort I, et al. Among authors: heijdra jm. Thromb Haemost. 2020 Jul;120(7):1056-1065. doi: 10.1055/s-0040-1710591. Epub 2020 Jun 1. Thromb Haemost. 2020. PMID: 32480417 Clinical Trial.
Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment.
Hazendonk HCAM, Heijdra JM, de Jager NCB, Veerman HC, Boender J, van Moort I, Mathôt RAA, Meijer K, Laros-van Gorkom BAP, Eikenboom J, Fijnvandraat K, Leebeek FWG, Cnossen MH; “OPTI-CLOT” and “WIN” study group. Hazendonk HCAM, et al. Among authors: heijdra jm. Haemophilia. 2018 May;24(3):460-470. doi: 10.1111/hae.13451. Epub 2018 Mar 24. Haemophilia. 2018. PMID: 29573506
Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease.
Atiq F, Heijdra J, Snijders F, Boender J, Kempers E, van Heerde WL, Maas DPMSM, Krouwel S, Schoormans SC, de Meris J, Schols SEM, van Galen KPM, van der Bom JG, Cnossen MH, Meijer K, Fijnvandraat K, Eikenboom J, Leebeek FWG. Atiq F, et al. Blood Adv. 2022 Sep 27;6(18):5317-5326. doi: 10.1182/bloodadvances.2021006757. Blood Adv. 2022. PMID: 35446929 Free PMC article.
18 results